Tibet Aim Pharm. (SZ:002826) Shang Hai Zheng Quan Bao·2025-10-28 21:49Core Viewpoint - The company, Xizang Yiming Xiya Pharmaceutical Technology Co., Ltd., has released its third-quarter financial report for 2025, ensuring the accuracy and completeness of the information disclosed [1][2]. Financial Data Summary - The company reported a 30.35% decrease in cash and cash equivalents compared to the beginning of the period, primarily due to investments in financial products [5]. - Trading financial assets increased by 280 million yuan, attributed to the purchase of short-term financial products [5]. - Accounts receivable notes decreased by 94.26%, reflecting the maturity and settlement of receivables [5]. - Prepayments increased by 3.75 million yuan, mainly due to payments made to suppliers and for engineering projects [5]. - Construction in progress doubled compared to the beginning of the period, due to payments for production line renovations [5]. - Accounts payable grew by 34.33%, linked to increased procurement and promotional service fees [5]. - Contract liabilities decreased by 57.03%, indicating a reduction in advance payments received [5]. - Tax liabilities increased by 13.06 million yuan, reflecting higher corporate income tax and VAT provisions [5]. - Other payables rose by 90.17%, primarily due to the recognition of obligations related to a stock incentive plan [5]. - Operating costs decreased by 48.35% year-on-year, due to the termination of third-party product collaborations [5]. - Financial expenses increased by 78.55%, driven by higher interest expenses from increased short-term borrowings [5]. - Investment income rose by 803,100 yuan, attributed to increased returns from financial product investments [5]. - Net cash flow from operating activities grew by 31.41%, due to increased sales and government subsidies [5]. Shareholder Information - As of the reporting period, the company’s shares held by the repurchase account amounted to 3,403,800 shares, representing 1.79% of the total share capital [7]. - A significant change in control occurred when Beijing Fuhai Enterprise Management Partnership acquired 23.00% of the company's shares from the previous controlling shareholder [7][8]. Board Meeting and Governance - The fourth board meeting was held on October 27, 2025, with all directors present, and the meeting complied with relevant laws and regulations [10][11]. - The board approved the third-quarter report, confirming that it accurately reflects the company's situation without any misleading statements [11][12].